| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:57 | WINTON LAND LIMITED: Winton - Capital Change Notice (ESOP) | - | NZX | ||
| Di | Esoteric Testing Market Worth $48.3 billion | MarketsandMarkets | 404 | PR Newswire | CHICAGO, June 4, 2024 /PRNewswire/ -- Esoteric Testing Market in terms of revenue was estimated to be worth $32.2 billion in 2024 and is poised to reach $48.3 billion by 2029, growing at... ► Artikel lesen | |
| Di | Pan African concludes 5-year wage agreement at Barberton Mines, ESOP matures: JSE-listed Pan African ... | - | Mining Weekly | ||
| Di | PAN AFRICAN RESOURCES PLC - Pan African concludes five-year wage agreement at Barberton mines and maturation of the Barberton mines ESOP | 2 | SENS | ||
| Di | Pan African Resources Plc - Pan African Concludes Five-Year Wage Agreement at Barberton Mines and Maturation of the Barberton Mines' Employee Share Ownership Plan (ESOP) | 39 | PR Newswire | Pan African Resources Plc - Pan African Concludes Five-Year Wage Agreement at Barberton Mines and Maturation of the Barberton Mines' Employee Share Ownership Plan (ESOP)
PR Newswire
LONDON... ► Artikel lesen | |
| Mo | Adaptimmune Therapeutics PLC: Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise | 291 | Newsfile | Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces the potential... ► Artikel lesen | |
| Mo | Operating company of Azbuka Vkusa, included in ESO list, receives 99% of its capital | 1 | Interfax | ||
| 23.05. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis | 30 | PR Newswire | Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b /2a trial of EP-104GI, provided the catalyst for the trial expansion
Early low-dose... ► Artikel lesen | |
| 23.05. | Abios drops new report: Euros & Copa America: How to maximize a summer of football with esoccer | 1 | European Gaming | ||
| 23.05. | Paytm's ESOP Cost Is More Than Net Loss: Know All About ESOP's | 1 | The Free Press Journal | ||
| 22.05. | Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 | 1 | CNW | ||
| 21.05. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis | 24 | PR Newswire | Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks
Data from the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks... ► Artikel lesen | |
| 21.05. | Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024 | 245 | PR Newswire | NANJING, China, May 21, 2024 /PRNewswire/ -- The 10th European Stroke Organization Congress (ESOC), held in Basel, Switzerland from May 15 to 17, 2024, showcased six studies on Sanbexin®... ► Artikel lesen | |
| 21.05. | Belatra agrees content partnership with Esofthall | 1 | European Gaming | ||
| 20.05. | Principal Buying ESOP Business From Ascensus | 1 | pulse2.com | ||
| 16.05. | Principal Financial to acquire Ascensus's ESOP business | 2 | Seeking Alpha | ||
| 15.05. | ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024 | 267 | Business Wire | Data on specific subgroups pave the way for new perspectives Continued commitment to conduct the phase 2/3 GREEN and phase 2b LIBERATE studies has been confirmed.
Regulatory News:
ACTICOR... ► Artikel lesen | |
| 15.05. | ESOC 2024: Neue Studie zeigt: Höheres Einkommen senkt Schlaganfall-Sterberisiko um ein Drittel | 515 | news aktuell | Basel, Schweiz (ots/PRNewswire) - Neue Forschungsergebnisse, die heute auf der 10th European Stroke Organisation Conference (ESOC) 2024 vorgestellt wurden, haben ergeben, dass Personen mit hohem Einkommen... ► Artikel lesen | |
| 15.05. | ESOC 2024: Higher income reduces stroke mortality risk by a third, new study shows | 265 | PR Newswire | BASEL, Switzerland, May 15, 2024 /PRNewswire/ -- New research, presented today at the 10th European Stroke Organisation Conference (ESOC) 2024, has revealed that high-income individuals have... ► Artikel lesen | |
| 14.05. | Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 | 1 | CNW |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 4.035 |
| GAMESTOP | 2.978 |
| NEL | 2.962 |
| EVOTEC | 2.772 |
| NVIDIA | 2.627 |
| BAYER | 2.058 |
| BYD | 1.471 |
| PLUG POWER | 1.399 |
| VOLKSWAGEN | 1.134 |
| DEUTSCHE LUFTHANSA | 1.038 |
| DEUTSCHE TELEKOM | 978 |
| RHEINMETALL | 974 |
| ALLIANZ | 950 |
| BIONTECH | 933 |
| SUPER MICRO COMPUTER | 854 |
| SIEMENS ENERGY | 726 |
| COMMERZBANK | 724 |
| DEUTSCHE BANK | 722 |
| AIXTRON SE | 710 |
| RWE | 687 |
| BASF | 657 |
| MERCEDES-BENZ | 602 |
| TESLA | 599 |
| THYSSENKRUPP | 583 |
| BARRICK GOLD | 567 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
